CMPX

0.68280.63%
CL

Carl Lee Gordon

Independent Chairman

Dr. Carl Lee Gordon, C.F.A., Ph.D., serves as an Independent Director at ADARx Pharmaceuticals, Inc. since January 2020. Dr. Gordon is Director of Clywedog Therapeutics, Inc. Dr. Gordon serves as an Independent Director of BlossomHill Therapeutics, Inc. since February 2021. Dr. Gordon serves as Director of Verdiva Bio Limited since October 23, 2024, Director of Sidewinder Therapeutics, Inc. since March 2021, Director of RayThera, Inc., Independent Director at Lomond Therapeutics Holdings, Inc., a privately held biotechnology company, since November 01, 2024, Director of Belenos Biosciences, Inc., Director at Avenzo Therapeutics, Inc. Director of Kumquat Biosciences Inc., Independent Director at Scribe Therapeutics Inc since 2022, Independent Director at Electra Therapeutics, Inc. since March 2019, Director at Garuda Therapeutics, Inc., Director of Seragon Pharmaceuticals Inc., Director of Frontera Therapeutics, Inc., Director of Alterome Therapeutics, Inc., Director at Bioverativ USA Inc., Protometrix, Inc., Amnis Corporation, Agensys, Inc. and Aragon Pharmaceuticals, Inc., Board of Directors at GentiBio, Inc., Independent Director at Singulex, Inc. since June 7, 2007, Director at X4 Pharmaceuticals, Inc. and Board of STAR Therapeutics, Inc. He is Board Observer of ENYO Pharma SA from August 2024, Board Observer at Cyrus Biotechnology, Inc. and Board Observer at Kartos Therapeutics, Inc. Dr. Gordon is a Managing Partner and Head of Global Private Equity of OrbiMed Advisors LLC from 2018, an investment firm, where he has served since January 1998. Dr. Gordon was Founding General Partner of OrbiMed Advisors LLC since joining the firm in 1998 to 2018 and was Founding General Partner, Managing Member, Managing Partner & Co-Head of Global Private Equity of OrbiMed Advisors LLC. Dr. Gordon has served on the board of directors of Compass Therapeutics Inc., a publicly held biopharmaceutical company, since September 2015 and served as Chair of the Board at Compass Therapeutics, Inc. since June 17, 2020 until January 2022. He serves on the Board of Celyn Therapeutics and Gwynant Therapeutics since September 2021. He previously served on the boards of directors of Adicet Bio, Inc. from August 2015 to April 2025, ArriVent BioPharma, Inc. from December 2022 to June 2025, Gemini Therapeutics Inc. from April 2016 until December 2022 (acquired by Disc Medicine, Inc.), Keros Therapeutics, Inc. from March 2020 to March 2026 and served as its Chairman since April 2023 until July 1, 2024, Kinnate Biopharma Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 until November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, Theseus Pharmaceuticals, Inc. from June 2018 until February 2024 (acquired by Concentra Biosciences, LLC), Director at Emendo Bio Inc. since 2019, Independent Director of Passage Bio, Inc. since September 2018 until February 2020, Director of Prevail Therapeutics Inc. since August 2017 until January 21, 2021, Director at SpringWorks Therapeutics, Inc. since August 2017 until 2019, Director of Good Start Genetics, Inc., Lead Independent Director at Turning Point Therapeutics, Inc. since April 2019 until November 2020 and served as its Director since May 2017 until November 2020, Director at ARMO Biosciences Inc since December 2012 until June 22, 2018, Director of ACADIA Pharmaceuticals Inc. since June 2000, Director of Complete Genomics, Inc. from August 2009 to June 6, 2012, Director of Amarin Corporation plc from May 23, 2008 to July 9, 2013, Director of Biocryst Pharmaceuticals, Inc. since March 11, 2004, Director of Acceleron Pharma Inc. from August 2006 to September 24, 2013, Director of Alector Inc. until June 8, 2019, Director of Intellia Therapeutics Inc. since August 2015 until July 25, 2017, Director of Selecta Biosciences, Inc. since 2010 until June 16, 2017, Director at Arsanis, Incorporated, Non-Executive Chairman of Arius Research Inc. since 2007, Director of Pacira Pharmaceuticals, Inc. from December 2006 to June 2, 2011, Director of Arius Research Inc. since February 28, 2006, Director of Igenica, Inc. and Helsinn Therapeutics (U.S.), Inc., Director at Adimab LLC until March, 2022 and Independent Director of Odyssey Therapeutics, Inc. since August 2021 until May 07, 2026. Dr. Gordon is Director of Clywedog Therapeutics, Inc. He serves as a Member of Advisory Board of New York City Investment Fund Manager, Inc. Dr. Gordon served as a Senior Biotechnology Analyst at Mehta and Isaly from March 1995 to December 1997. Dr. Gordon was employed in the Bioinformatics Division of Imclone Systems from 1987 to 1988. Dr. Gordon is active in both private equity and small-capitalization public equity investments. He was included on the Forbes Midas List of top 100 venture capital Investors from 2014 to 2018. Dr. Gordon earned a B.A. in chemistry from Harvard College in May 1987, a Ph.D. in molecular biology from the Massachusetts Institute of Technology in 1993 and was a Postdoctoral Fellow at the Rockefeller University in 1995. He holds a Certified Financial Analyst designation.

公司职务